Disease/Infection News

RSS

Remdesivir likely to be highly effective treatment for COVID-19

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists.

14 Dec 2020

Researchers test commercial assays to detect SARS-CoV-2 antibodies six months after infection

Researchers at the Hospices Civils de Lyon (HCL) in France found that people infected with SARS-CoV-2 can develop antibodies that persist for up to six months. After testing commercial assays to detect antibodies, the Wantai antibody assay has a positivity rate of 100%.

14 Dec 2020

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

The focus is increasingly moving towards vaccine roll-out as the world faces the real possibility of the second year of social and economic restrictions.

14 Dec 2020

COVID-19 vaccination may potentially cut hospitalizations, deaths by 60% in Ontario, Canada

A new study suggests an impact of the COVID-19 vaccine on SARS-CoV-2 attack rate, and hospitalizations, even with no protection against infection.

14 Dec 2020

Risk factors for COVID-19 vaccine acceptance

A recent study adds more evidence to the supposition that willingness to accept the COVID-19 vaccine depends on a variety of factors.

14 Dec 2020

Epitope “megapools” could help determine role T cell immunity plays in COVID-19

Researchers in the United States and Australia have conducted a comprehensive analysis of the epitope recognition patterns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans.

14 Dec 2020

60-second breath test to detect COVID-19 with IONICON PTR-TOFMS

Singapore start-up develops fast breath test based on PTR-TOF technology.

From Ionicon Analytik Ges.m.b.H. 14 Dec 2020

Prior T cell immunity to SARS-CoV-2 unlikely to be the result of seasonal coronavirus infection

Scientists have suggested that a proportion of the population have pre-existing immunity to COVID-19 because of T cells primed against SARS-CoV-2 antigens.

14 Dec 2020

D614G mutation promotes lysosomal trafficking of SARS-CoV-2 spike protein

In the current COVID-19 pandemic, SARS-CoV-2 has led to millions of infections worldwide, with over 1.5 million deaths.

14 Dec 2020

Recovered COVID-19 patients exhibit persistent cellular immunity

Researchers at The Rockefeller University in New York have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – triggers persistent T cell responses that last for at least six months.

14 Dec 2020

SARS-CoV-2 Nsp3 protease activity and nanobody inhibitor development

A new study published in the pre-print server bioRxiv* explores the viral enzyme PLpro, encoded in the nonstructural protein nsp3, and its inhibitors. T

14 Dec 2020

RNA editing within host linked to SARS-CoV-2 variants

Since the start of the COVID-19 pandemic, the causative virus, SARS-CoV-2, has undergone several mutations.

14 Dec 2020

Study implicates diaphragm dysfunction as a potential cause for prolonged COVID-19 impairments

Using a neuromuscular ultrasound technique, researchers reveal that COVID-19 patients have a very high prevalence of diaphragm dysfunction.

14 Dec 2020

High blood pressure may accelerate cognitive decline at any age

A new study published in Hypertension has found that high blood pressure at any age for any duration may contribute to cognitive decline.

14 Dec 2020

Households are a high-risk setting for SARS-CoV-2 transmission

The results of a new study have confirmed that households, and other crowded indoor environments, are high-risk settings for SARS-CoV-2 transmission.

14 Dec 2020

GlobalData: U.S. cannot wait on vaccines to fight COVID-19

Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has reported its highest one-day COVID-19 death tally;

14 Dec 2020

Report: COVID-19 has had little positive impact on perceptions of pharmaceutical companies

A report launched today by pharmaceutical company Takeda UK reveals that, despite heightened public and media attention on the industry’s efforts to develop vaccines and treatments, the COVID-19 pandemic has had little positive impact on perceptions of pharmaceutical companies.

14 Dec 2020

Disease/Infection News

Remdesivir likely to be highly effective treatment for COVID-19

Researchers test commercial assays to detect SARS-CoV-2 antibodies six months after infection

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

COVID-19 vaccination may potentially cut hospitalizations, deaths by 60% in Ontario, Canada

Risk factors for COVID-19 vaccine acceptance

Epitope “megapools” could help determine role T cell immunity plays in COVID-19

60-second breath test to detect COVID-19 with IONICON PTR-TOFMS

Prior T cell immunity to SARS-CoV-2 unlikely to be the result of seasonal coronavirus infection

D614G mutation promotes lysosomal trafficking of SARS-CoV-2 spike protein

Recovered COVID-19 patients exhibit persistent cellular immunity

SARS-CoV-2 Nsp3 protease activity and nanobody inhibitor development

RNA editing within host linked to SARS-CoV-2 variants

Study implicates diaphragm dysfunction as a potential cause for prolonged COVID-19 impairments

High blood pressure may accelerate cognitive decline at any age

Households are a high-risk setting for SARS-CoV-2 transmission

GlobalData: U.S. cannot wait on vaccines to fight COVID-19

Report: COVID-19 has had little positive impact on perceptions of pharmaceutical companies

Study: Lack of water puts health care workers and patients at higher risk of COVID-19 infection

Digital chest drainage systems could help reduce COVID-19 spread, research shows

New platform allows travelers from any country to book Covid-19 pre-travel tests

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Latest News